MPE has developed a series of Q&As for patients and patient advocates covering treatment updates and relevant advocacy topics. Check the following factsheets on:
Q&As
Minimal Residual Disease (MRD)
MRD stands for Minimal Residual Disease. Find the answers to the most frequently asked questions by patients about MRD. (March 2023)
Chimeric Antigen Receptor T cell (CAR-T) therapy
CAR-T is a form of immunotherapy currently approved and under investigation for the treatment of myeloma. Find the answers to the most frequently asked questions by patients about CAR-T. (June 2022)
SARS-CoV-2 (COVID-19) Vaccination and Treatment
The SARS-CoV-2 (COVID-19) pandemic raised many questions, especially around vaccination. You can find the answers to the most frequently asked questions about the current approved vaccines and treatments in Europe. (February 2022)
European Union (EU) Funded Projects
The European Union is a political and economic union of 27 countries designed to enhance social cohesion among its members. You can find the answers to the most frequently asked questions about the funded projects in this Q&A. (July 2021)
Health Technology Assessment (HTA)
This Myeloma Patients Europe Q&A explains the role of Health Technology Assessment (HTA) in Europe. It covers what HTA is and provides a general picture of how it works within the context of reimbursement systems. (March 2018)
Horizon 2020 is a large-scale EU Research and Innovation Programme. It funds a wide range of different projects relating to science, innovation and tackling societal challenges. This is a Q&A explaining MMpredict and the role of the project consortium in further detail.
Subscribe to
our newsletter!